MyMedR

Displaying all 4 publications

Abstract:

Sort:

Outcome of alternative approach to displaced acetabular fractures

Park KS, Chan CK, Lee GW, Ahn HW, Yoon TR

Injury, 2017 Feb;48(2):388-393.
PMID: 27914663 DOI: 10.1016/j.injury.2016.11.029

INTRODUCTION: Anatomical reduction of displaced acetabular fracture is not without its' limitations and complications. This study is conducted to assess clinical and radiological outcomes as well as complications of treating displaced acetabular fractures with emphasis on anatomical reduction in weight-bearing area, mainly the posterior column, and imperfect reduction of the anterior column is acceptable. However, stability of both columns is mandatory.
METHODS: It was a retrospective study carried out in a Level 1 arthroplasty and trauma centre. 23 patients (17 males, 6 females) with average age of 50.1 years (range, 36-68 years) with displaced acetabular fracture treated with combined incisions and plate-cable systems were included. There were 3 elementary and 18 associated fractures according to Letournel classification. Average follow-up was 23.5 months (range, 12-38.7 months). Mean operation time was 160min (range: 75-320min). Functional scores were evaluated using Harris Hip Score (HHS) whilst reduction was assessed by Matta criteria. Any displacement of reduction, osteoarthritis, heterotopic ossification, and other complications was recorded.
RESULT: 65.2% (15/23) of the patients obtained excellent HHS and 21.7% (5/23) had good HHS. There were 12 anatomical, 6 imperfect, and 5 poor reductions. No displacement was recorded in final follow-up. Complications documented: three lateral femoral cutaneous nerve injuries, two conversions to total hip arthroplasty, three Brooker stage 1 heterotrophic ossification, one pulmonary embolism and one screw irritation. No incidence of wound breakdown, infection and radiological osteoarthritis was reported.
CONCLUSIONS: Imperfect reduction of the anterior column provided clinical outcomes that are as good as total anatomical reduction. This approach minimizes soft tissue damage and reduces perioperative morbidities.
Current advances and future prospects of in-situ desulfurization processes in oxy-fuel combustion reactors

Go ES, Ling JLJ, Solanki BS, Ahn H, Show PL, Lee SH

Environ Res, 2024 Dec 15;263(Pt 1):119982.
PMID: 39270960 DOI: 10.1016/j.envres.2024.119982

Oxy-fuel circulating fluidized bed combustion is known as one of the most potent fuel combustion technologies that capture ultra-low greenhouse gases and pollutant emissions. While many investigations have been conducted for carbon capturing, the associated in-situ desulfurization process using calcium-based sorbents should also be underlined. This paper critically reviews the effects of changes in the operating environment on in-situ desulfurization processes compared to conventional air combustion. A comprehensive understanding of the process, encompassing hydrodynamic, physical and chemical aspects can be a guideline for designing the oxy-fuel combustion process with effective sulfur removal, potentially eliminating the need of a flue gas desulfurization unit. Results from thermogravimetric analyzers and morphological changes of calcium-based materials were presented to offer an insight into the sulfation mechanisms involved in the oxy-fuel circulating fluidized beds. Recently findings suggested that in-situ direct desulfurization is influenced not only by the desulfurization kinetics but also by the fluidization characteristics of calcium-based materials. Therefore, a complex reaction analysis that incorporated oxy-combustion reactions, computational fluid dynamics modeling, in-situ desulfurization reaction models and particle behavior can provide a thorough understanding of desulfurization processes across the reactor. Meanwhile, machine learning as a robust tool to predict desulfurization efficiency and improve operational flexibility should be applied with consideration of environmental improvement and economic feasibility.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park K, Vansteenkiste J, Lee KH, Pentheroudakis G, Zhou C, Prabhash K, et al.

Ann Oncol, 2020 02;31(2):191-201.
PMID: 31959336 DOI: 10.1016/j.annonc.2019.10.026

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries.
Fulltext Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, et al.

ESMO Open, 2023 Jun;8(3):101541.
PMID: 37178669 DOI: 10.1016/j.esmoop.2023.101541

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.